Inari Medical Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Inari Medical, Inc. (NARI) Tops Q4 EPS by 12c, Revenues Beat; Offers 1Q & FY21 Revenues Guidance Above Consensus
March 9, 2021 4:06 PM ESTInari Medical, Inc. (NASDAQ: NARI) reported Q4 EPS of $0.13, $0.12 better than the analyst estimate of $0.01. Revenue for the quarter came in at $48.6 million versus the consensus estimate of $41.08 million.
Fourth Quarter Revenue and Business Highlights:
Treated a record 4,600 patients, up 24% sequentially, driving revenue of $48.6 million, which was up 26% sequentially and 144% over the prior year period.Introduction of multiple new products... More